NervGen registers Phase 3 RESTORE trial of NVG-291 in chronic spinal cord injury

NervGen Pharma had one registry update during the week, a newly posted Phase 3 study of its lead candidate.

• NVG-291, an investigational peptide, is being tested in "RESTORE" (NCT07799532), a Phase 3, randomized, double-blind, placebo-controlled study in adults with chronic cervical motor-incomplete spinal cord injury. The trial is designed as a randomized, double-blind, placebo-controlled, multicenter study looking at how the drug performs and behaves in the body in this patient population.¹ The study is listed as not yet recruiting, with an estimated start date of September 23, 2026, and plans to enroll about 150 participants at up to 60 sites in the United States and Canada, randomized 1:1 to NVG-291 or placebo.¹ The primary endpoint measures hand function change from baseline to Week 12 using the "combined Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) Quantitative Prehension (QtP) score," a composite of four Prehension Performance task scores for each hand, with a possible range of 0 to 40.¹